Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 10/20 | 0.41 |
| ▸ | CA2 | P00918 | 10/20 | 0.41 |
| ▸ | CA4 | P22748 | 10/20 | 0.41 |
| ▸ | CA9 | Q16790 | 10/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | MC4R | P32245 | 2/20 | 0.38 |
| ▸ | MC3R | P41968 | 2/20 | 0.38 |
| ▸ | MC1R | Q01726 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28474456 | 0.79 | CMA1 (0.42) | ABCB1CA1CA2CA4CA9 | |
| SCHEMBL29060292 | 0.76 | CA1 (0.46) | ABCB1CA1CA2CA4CA9 | |
| SCHEMBL590923 | 0.71 | CA1 (0.62) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL28045116 | 0.71 | CA1 (0.62) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL28567291 | 0.71 | ABCB1 (0.48) | ABCB1CA1CA2CA4CA9 | |
| SCHEMBL20575828 | 0.70 | ABHD6 (0.52) | ABCB1MC4RMC3RMC1R | |
| SCHEMBL3576211 | 0.69 | CA1 (0.54) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL2086686 | 0.69 | CA1 (0.54) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL21010215 | 0.69 | KDM4E (0.40) | ABCB1MC4R | |
| SCHEMBL28405413 | 0.69 | ABCB1 (0.49) | ABCB1CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745427-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080090806-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090806-A1 | Cgrp Receptor Antagonists | CCKBR, BDKRB1, BDKRB2 | ABCB1 652/4885CA1 3498/4885CA2 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.